The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of nivolumab (Opdivo) monotherapy for the adjuvant treatment of patients at least 12 years of age with completely resected stage IIB or IIC melanoma.
2023
Fianlimab Combined With Cemiplimab Elicits Durable Responses in Advanced Melanoma
In an interview with Targeted Oncology, Omid Hamid, MD, discussed the efficacy of fianlimab in combination with cemiplimab for advanced melanoma. The results of the study show new possibilities for treating patients who have failed adjuvant anti PD-1 therapy.
Using a Patient’s Immune System to Treat Skin Cancer
Advancements have been made over the last decade in the use of immunotherapy for the treatment of skin cancers including melanoma, squamous cell carcinoma and Merkel cell carcinoma.
Some Patients With Low-Risk Melanoma in Situ May Live Longer Than General Population
Significant detection of low-risk melanoma in situ (MIS) among health-seeking individuals may help those who become diagnosed with low-risk MIS to live longer than those in the general population without history of MIS, according to study findings published in the Journal of the American Medical Association Dermatology.